3M PFAS Health Science Publication Citations

May 15, 2025

[1] Rosen EM, Crawford L, Hoffmann S, Skidmore B, Porter AK, Halperin SA, Longnecker MP. Systematic review and meta-analysis of epidemiologic data on infectious disease in relation to exposure to twelve perfluoroalkyl substances (PFAS). International Journal of Hygiene and Environmental Health. 2025 2025/05/01/;266:114571.

[2] Khan Y, Schmidt AM, Oldro KJ, Zhu X, Kramer AR, Hamilton SR, Bleil KO, Krisko RM, Zitzow JD, Tian Y, Chang SC, Walter V, Cohen SM, Gonzalez FJ, Patterson AD, Peters JM. Differential hepatic activation of mouse and human peroxisome proliferator-activated receptor-alpha by perfluorohexane sulfonate. Toxicological sciences : an official journal of the Society of Toxicology. 2025 Feb 26.

[3] Campbell JL, Jr., Linakis MW, Porter AK, Rosen EM, Logan PW, Kleinschmidt SE, Andres KL, Chang S, Taiwo OA, Olsen GW, Clewell HJ, 3rd, Longnecker MP. Evaluation of the validity of a perfluorooctane sulfonic acid exposure reconstruction using a measured serum concentration among workers with a wide range of exposure. Annals of work exposures and health. 2025 Feb 25;69(2):160-72.

[4] Pierpont TM, Elmore J, Redko A, Anannya O, Imbiakha B, O'Hare K, Villanueva A, Anronikov S, Bondah N, Chang S, Sahler J, August A. Effects of Perfluorohexane Sulfonate Exposure on Immune Cell Populations in Naive Mice. ImmunoHorizons. 2024 Aug 1;8(8):538-49.

[5] Aali G, Porter AK, Hoffmann S, Longnecker MP, Shokraneh F. Gestational diabetes mellitus in relation to serum per- and polyfluoroalkyl substances: A scoping review to evaluate the need for a new systematic review. F1000Research. 2024;12:1595.

[6] Alexander BH, Ryan A, Church TR, Kim H, Olsen GW, Logan PW. Mortality and cancer incidence in perfluorooctanesulfonyl fluoride production workers. Am J Ind Med. 2024 Apr;67(4):321-33.

[7] Porter AK, Kleinschmidt SE, Andres KL, Reusch CN, Krisko RM, Taiwo OA, Olsen GW, Longnecker MP. Occurrence of COVID-19 and serum per- and polyfluoroalkyl substances: A case-control study among workers with a wide range of exposures. Global Epidemiol. 2024 7:100137.

[8] Andres KL, Olsen GW, Krisko RM, Nunnally MC, Boeding RR, Leniek KL, Taiwo OA. An investigation of 3M Cordova, IL production worker's per- and polyfluoroalkyl substances biomonitoring results and mortality experience. Int J Hyg Environ Health. 2024 Jan 19;256:114321.

[9] Olsen GW, Chang S, Taiwo OA. Comment on "A Nested Case-Control Study of Serum Per- and Polyfluoroalkyl Substances and Testicular Germ Cell Tumors among U.S. Air Force Servicemen". Environ Health Perspect. 2023 Sep;131(9):98001.

[10] Olsen GW, Chang S, Taiwo OA. Response to "Comment on 'Comment on "A Nested Case-Control Study of Serum Per- and Polyfluoroalkyl Substances and Testicular Germ Cell Tumors among U.S. Air Force Servicemen"'". Environ Health Perspect. 2023 Dec;131(12):128002.

[11] Pierpont TM, Limper C, Elmore J, Redko A, Anannya O, Imbiakha B, Villanueva A, Anronikov S, Bondah N, Chang S, Sahler J, August A. Effects of PFOS and cyclophosphamide exposure on immune homeostasis in mice. Immunobiology. 2023 2023/05/01/;228(3):152356.

[12] Crawford L, Halperin SA, Dzierlenga MW, Skidmore B, Linakis MW, Nakagawa S, Longnecker MP. Systematic review and meta-analysis of epidemiologic data on vaccine response in relation to exposure to five principal perfluoroalkyl substances. Environ Int. 2023 Feb;172:107734.

[13] Antoniou E, Colnot T, Zeegers M, Dekant W. Immunomodulation and exposure to per- and polyfluoroalkyl substances: an overview of the current evidence from animal and human studies. Arch Toxicol. 2022 Aug;96(8):2261-85.
[14] Colnot T, Dekant W. Commentary: cumulative risk assessment of perfluoroalkyl carboxylic acids and perfluoralkyl sulfonic acids: what is the scientific support for deriving tolerable exposures by assembling 27 PFAS into 1 common assessment group? Arch Toxicol. 2022 Nov;96(11):3127-39.
[15] Su S, Billy LJ, Chang S, Gonzalez FJ, Patterson AD, Peters JM. The role of mouse and human peroxisome proliferator-activated receptor-α in modulating the hepatic effects of perfluorooctane sulfonate in mice. Toxicol. 2022;15(465):153056.
[16] Porter AK, Kleinschmidt SE, Andres KL, Reusch CN, Krisko RM, Taiwo OA, Olsen GW, Longnecker MP. Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances. Environ Int. 2022 Nov;169:107537.
[17] Colnot T, Dekant W. Issues in the hazard and risk assessment of perfluoroalkyl substance mixtures. Toxicol Lett. 2021 Oct 16;353:79-82.
[18] Andersen ME, Hagenbuch B, Apte U, Corton JC, Fletcher T, Lau C, Roth WL, Staels B, Vega GL, Clewell HJ, 3rd, Longnecker MP. Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms. Toxicology. 2021 Jul 8;459:152845.
[19] Torres L, Redko A, Limper C, Imbiakha B, Chang S, August A. Effect of Perfluorooctanesulfonic acid (PFOS) on immune cell development and function in mice. Immunol Lett. 2021 May;233:31-41.
[20] Ruggiero MJ, Miller H, Idowu JY, Zitzow JD, Chang SC, Hagenbuch B. Perfluoroalkyl Carboxylic Acids Interact with the Human Bile Acid Transporter NTCP. Livers. 2021 Dec;1(4):221-9.
[21] Dzierlenga MW, Keast DR, Longnecker MP. The concentration of several perfluoroalkyl acids in serum appears to be reduced by dietary fiber. Environ Int. 2021 Jan;146:106292.
[22] Bjork JA, Dawson DA, Krogstad JO, Wallace KB. Transcriptional Effects of Binary Combinations of PFAS in FaO Cells. Toxicology. 2021 Oct 22:152997.
[23] Andersen ME, Mallick P, Clewell HJ, 3rd, Yoon M, Olsen GW, Longnecker MP. Using quantitative modeling tools to assess pharmacokinetic bias in epidemiological studies showing associations between biomarkers and health outcomes at low exposures. Environ Res. 2021 Apr 19;197:111183.
[24] Zhang L, Rimal B, Nichols RG, Tian Y, Smith PB, Hatzakis E, Chang SC, Butenhoff JL, Peters JM, Patterson AD. Perfluorooctane sulfonate alters gut microbiota-host metabolic homeostasis in mice. Toxicology. 2020 Feb 15;431:152365.
[25] Dzierlenga MW, Moreau M, Song G, Mallick P, Ward PL, Campbell JL, Housand C, Yoon M, Allen BC, Clewell HJ, 3rd, Longnecker MP. Quantitative bias analysis of the association between subclinical thyroid disease and two perfluoroalkyl substances in a single study. Environ Res. 2020 Mar;182:109017.
[26] Dzierlenga MW, Crawford L, Longnecker MP. Birth weight and perfluorooctane sulfonic acid: a random-effects meta-regression analysis. Environmental Epidemiology. 2020;4(3):e095.
[27] Dzierlenga MW, Allen BC, Clewell HJ, 3rd, Longnecker MP. Pharmacokinetic bias analysis of an association between clinical thyroid disease and two perfluoroalkyl substances. Environ Int. 2020 May 11;141:105784.
[28] Chang S, Parker GA, Kleinschmidt SE, Olsen GW, Ley CA, Taiwo OA. A Pathology Review of the Lower Gastrointestinal Tract in Relation to Ulcerative Colitis in Rats and Cynomolgus Macaques Treated With Ammonium Perfluorooctanoate. Toxicol Pathol. 2020 Jun;48(4):593-602.
[29] Pouwer MG, Pieterman EJ, Chang SC, Olsen GW, Caspers MPM, Verschuren L, Jukema JW, Princen HMG. Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in

APOE*3-Leiden.CETP Mice. Toxicological sciences : an official journal of the Society of Toxicology. 2019 Apr 1;168(2):519-34.
[30] Dzierlenga MW, Allen BC, Ward PL, Clewell HJ, 3rd, Longnecker MP. A model of functional thyroid disease status over the lifetime. PLoS One. 2019;14(7):e0219769.
[31] Olsen GW. Re: Health Status of Workers Exposed to Perfluorinated Alkylate Substances. J Occup Environ Med. 2018 Oct;60(10):e563-e6.
[32] Lange CC. Anaerobic biotransformation of N-methyl perfluorobutanesulfonamido ethanol and N-ethyl perfluorooctanesulfonamido ethanol. Environ Toxicol Chem. 2018 Mar;37(3):768-79.
[33] Convertino M, Church TR, Olsen GW, Liu Y, Doyle E, Elcombe CR, Barnett AL, Samuel LM, MacPherson IR, Evans TRJ. Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA). Toxicological sciences : an official journal of the Society of Toxicology. 2018 May 1;163(1):293-306.
[34] Chang S, Butenhoff JL, Parker GA, Coder PS, Zitzow JD, Krisko RM, Bjork JA, Wallace KB, Seed JG. Reproductive and developmental toxicity of potassium perfluorohexanesulfonate in CD-1 mice. Reprod Toxicol. 2018 Jun;78:150-68.
[35] Zhao W, Zitzow JD, Weaver Y, Ehresman DJ, Chang SC, Butenhoff JL, Hagenbuch B. Organic Anion Transporting Polypeptides Contribute to the Disposition of Perfluoroalkyl Acids in Humans and Rats. Toxicological sciences : an official journal of the Society of Toxicology. 2017 Mar 1;156(1):84-95.
[36] Ruark CD, Song G, Yoon M, Verner MA, Andersen ME, Clewell HJ, 3rd, Longnecker MP. Quantitative bias analysis for epidemiological associations of perfluoroalkyl substance serum concentrations and early onset of menopause. Environ Int. 2017 Feb;99:245-54.
[37] Olsen GW, Mair DC, Lange CC, Harrington LM, Church TR, Goldberg CL, Herron RM, Hanna H, Nobiletti JB, Rios JA, Reagen WK, Ley CA. Per- and polyfluoroalkyl substances (PFAS) in American Red Cross adult blood donors, 2000-2015. Environ Res. 2017 Aug;157:87-95.
[38] Ngueta G, Longnecker MP, Yoon M, Ruark CD, Clewell HJR, Andersen ME, Verner MA. Quantitative bias analysis of a reported association between perfluoroalkyl substances (PFAS) and endometriosis: The influence of oral contraceptive use. Environ Int. 2017 Jul;104:118-21.
[39] Chang S, Mader BT, Lindstrom KR, Lange CC, Hart JA, Kestner TA, Schulz JF, Ehresman DJ, Butenhoff JL. Perfluorooctanesulfonate (PFOS) Conversion from N-Ethyl-N-(2-hydroxyethyl)-perfluorooctanesulfonamide (EtFOSE) in male Sprague Dawley rats after inhalation exposure. Environ Res. 2017 May;155:307-13.
[40] Chang S, Allen BC, Andres KL, Ehresman DJ, Falvo R, Provencher A, Olsen GW, Butenhoff JL. Evaluation of Serum Lipid, Thyroid, and Hepatic Clinical Chemistries in Association With Serum Perfluorooctanesulfonate (PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS. Toxicological sciences : an official journal of the Society of Toxicology. 2017 Apr 1;156(2):387-401.
[41] Butenhoff JL, Olsen GW, Chang S. Toxicological response of Sprague Dawley rats from inhalation exposure to perfluorooctane sulfonyl fluoride (POSF). Toxicol Lett. 2017 Apr 5;271:38-49.
[42] Bagley BD, Chang SC, Ehresman DJ, Eveland A, Zitzow JD, Parker GA, Peters JM, Wallace KB, Butenhoff JL. Perfluorooctane Sulfonate-Induced Hepatic Steatosis in Male Sprague Dawley Rats Is Not Attenuated by Dietary Choline Supplementation. Toxicological sciences : an official journal of the Society of Toxicology. 2017 Dec 1;160(2):284-98.
[43] Chang ET, Adami HO, Boffetta P, Wedner HJ, Mandel JS. A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and immunological health conditions in humans. Crit Rev Toxicol. 2016 Apr;46(4):279-331.
[44] Zhang L, Krishnan P, Ehresman DJ, Smith PB, Dutta M, Bagley BD, Chang SC, Butenhoff JL, Patterson AD, Peters JM. Editor's Highlight: Perfluorooctane Sulfonate-Choline Ion Pair

Formation: A Potential Mechanism Modulating Hepatic Steatosis and Oxidative Stress in Mice. Toxicological sciences : an official journal of the Society of Toxicology. 2016 Sep;153(1):186-97.
[45] Princen HMG, Pouwer MG, Pieterman EJ. Comment on "Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice" by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46-54. Toxicol Rep. 2016 //;3:306-9.
[46] Zhao W, Zitzow JD, Ehresman DJ, Chang SC, Butenhoff JL, Forster J, Hagenbuch B. Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl Sulfonates in Humans and Rats. Toxicological sciences : an official journal of the Society of Toxicology. 2015 Aug;146(2):363-73.
[47] Wu H, Yoon M, Verner M-A, Xue J, Luo M, Andersen ME, Longnecker MP, Clewell III HJ. Can the observed association between serum perfluoroalkyl subtances and delayed menarche be explained on the basis of puberty-related changes in physiology and pharmacokinetics? Environ Int. 2015;82:61-8.
[48] Verner MA, Longnecker MP. Comment on "enhanced elimination of perfluorooctanesulfonic Acid by menstruating women: evidence from population-based pharmacokinetic modeling". Environ Sci Technol. 2015 May 5;49(9):5836-7.
[49] Verner MA, Loccisano AE, Morken NH, Yoon M, Wu H, McDougall R, Maisonet M, Marcus M, Kishi R, Miyashita C, Chen MH, Hsieh WS, Andersen ME, Clewell HJ, 3rd, Longnecker MP. Associations of Perfluoroalkyl Substances (PFAS) with Lower Birth Weight: An Evaluation of Potential Confounding by Glomerular Filtration Rate Using a Physiologically Based Pharmacokinetic Model (PBPK). Environ Health Perspect. 2015 Dec;123(12):1317-24.
[50] Shabalina IG, Kramarova TV, Mattsson CL, Petrovic N, Rahman Qazi M, Csikasz RI, Chang SC, Butenhoff J, DePierre JW, Cannon B, Nedergaard J. The Environmental Pollutants Perfluorooctane Sulfonate and Perfluorooctanoic Acid Upregulate Uncoupling Protein 1 (UCP1) in Brown-Fat Mitochondria Through a UCP1-Dependent Reduction in Food Intake. Toxicological sciences : an official journal of the Society of Toxicology. 2015 Aug;146(2):334-43.
[51] Olsen GW, Ley CA. Prostate Cancer and PFOA. J Occup Environ Med. 2015 Jun;57(6):e60.
[52] Olsen GW. PFAS biomonitoring in higher exposed populations. In: DeWitt J, ed. *Toxicological Effects of Perfluoroalkyl and Polyfluoroalkyl Substances*. Switzerland: Springer International Publishing 2015:77-125.
[53] Liu Y, Pereira AS, Beesoon S, Vestergren R, Berger U, Olsen GW, Glynn A, Martin JW. Temporal trends of perfluorooctanesulfonate isomer and enantiomer patterns in archived Swedish and American serum samples. Environ Int. 2015 Feb;75:215-22.
[54] Liew Z, Ritz B, von Ehrenstein OS, Bech BH, Nohr EA, Fei C, Bossi R, Henriksen TB, Bonefeld-Jorgensen EC, Olsen J. Attention deficit/hyperactivity disorder and childhood autism in association with prenatal exposure to perfluoroalkyl substances: a nested case-control study in the Danish National Birth Cohort. Environ Health Perspect. 2015 Apr;123(4):367-73.
[55] Butenhoff JL, Rodricks JV. Human Health Risk Assessment of Perfluoroalkyl Acids. In: DeWitt J, ed. *Toxicological Effects of Perfluoroalkyl and polyfluoroalkyl Substances*. Switzerland: Springer International Publishing 2015:363-418.
[56] Botelho SA, Saghafian M, Pavlova S, Hassan M, DePierre JW, Abedi-Valugerdi M. Complement activation is involved in the hepatic injury caused by by high-dose exposure of mice to perfluorooctanoic acid Chemosphere. 2015;129:225-31.
[57] Chang ET, Adami HO, Boffetta P, Cole P, Starr TB, Mandel JS. A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and cancer risk in humans. Crit Rev Toxicol. 2014 May;44 Suppl 1:1-81.

[58] Yao PL, Ehresman DJ, Rae JM, Chang SC, Frame SR, Butenhoff JL, Kennedy GL, Peters JM. Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid. Toxicology. 2014 Dec 4;326:62-73.
[59] Raleigh KK, Alexander BH, Olsen GW, Ramachandran G, Morey SZ, Church TR, Logan PW, Scott LL, Allen EM. Mortality and cancer incidence in ammonium perfluorooctanoate production workers. Occup Environ Med. 2014 Jul;71(7):500-6.
[60] Liew Z, Ritz B, Bonefeld-Jorgensen EC, Henriksen TB, Nohr EA, Bech BH, Fei C, Bossi R, von Ehrenstein OS, Streja E, Uldall P, Olsen J. Prenatal exposure to perfluoroalkyl substances and the risk of congenital cerebral palsy in children. Am J Epidemiol. 2014 Sep 15;180(6):574-81.
[61] Caverly Rae JM, Frame SR, Kennedy GL, Butenhoff JL, Chang SC. Pathology review of proliferative lesions of the exocrine pancreas in two chronic feeding studies in rats with ammonium perfluorooctanoate. Toxicol Rep. 2014;1:85-91.
[62] Butenhoff JL, Kennedy GL, Jung R, Chang SC. Evaluation of perfluorooctanoate for potential genotoxicity. Toxicol Rep. 2014;1:252-70.
[63] Bogdanska J, Sundstrom M, Bergstrom U, Borg D, Abedi-Valugerdi M, Bergman A, DePierre J, Nobel S. Tissue distribution of ^{35}S-labelled perfluorobutanesulfonic acid in adult mice following dietary exposure for 1-5 days. Chemosphere. 2014 Mar;98:28-36.
[64] Vanden Heuvel JP. Comment on "associations between PFOA, PFOS and changes in the expression of genes involved in cholesterol metabolism in humans" by Fletcher et al., Environment International 57-58 (2013) 2-10. Environ Int. 2013 Nov;61:150-3.
[65] Qazi MR, Hassan M, Nelson BD, Depierre JW, Abedi-Valugerdi M. Sub-acute, moderate-dose, but not short-term, low-dose dietary pre-exposure of mice to perfluorooctanoate aggravates concanavalin A-induced hepatitis. Toxicol Lett. 2013 May 10;219(1):1-7.
[66] Qazi MR, Hassan M, Nelson BD, DePierre JW, Abedi-Valugerdi M. Both sub-acute, moderate-dose and short-term, low-dose dietary exposure of mice to perfluorooctane sulfonate exacerbates concanavalin A-induced hepatitis. Toxicol Lett. 2013 Feb 13;217(1):67-74.
[67] Loccisano AE, Longnecker MP, Campbell JL, Jr., Andersen ME, Clewell HJ, 3rd. Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. J Toxicol Environ Health A. 2013;76(1):25-57.
[68] Albrecht PP, Torsell NE, Krishnan P, Ehresman DJ, Frame SR, Chang SC, Butenhoff JL, Kennedy GL, Gonzalez FJ, Peters JM. A species difference in the peroxisome proliferator-activated receptor alpha-dependent response to the developmental effects of perfluorooctanoic acid. Toxicological sciences : an official journal of the Society of Toxicology. 2013 Feb;131(2):568-82.
[69] Zobel LR, Olsen GW, Butenhoff JL. Perfluorinated compounds and immunotoxicity in children. JAMA. 2012 May 9;307(18):1910; author reply -1.
[70] Sundstrom M, Chang SC, Noker PE, Gorman GS, Hart JA, Ehresman DJ, Bergman A, Butenhoff JL. Comparative pharmacokinetics of perfluorohexanesulfonate (PFHxS) in rats, mice, and monkeys. Reprod Toxicol. 2012 Jul;33(4):441-51.
[71] Sundstrom M, Bogdanska J, Pham HV, Athanasios V, Nobel S, McAlees A, Eriksson J, DePierre JW, Bergman A. Radiosynthesis of perfluorooctanesulfonate (PFOS) and perfluorobutanesulfonate (PFBS), including solubility, partition and adhesion studies. Chemosphere. 2012 May;87(8):865-71.
[72] Reiner JL, O'Connell SG, Butt CM, Mabury SA, Small JM, De Silva AO, Muir DC, Delinsky AD, Strynar MJ, Lindstrom AB, Reagen WK, Malinsky M, Schafer S, Kwadijk CJ, Schantz MM, Keller JM. Determination of perfluorinated alkyl acid concentrations in biological standard reference materials. Anal Bioanal Chem. 2012 Nov;404(9):2683-92.

[73] Raymer JH, Michael LC, Studabaker WB, Olsen GW, Sloan CS, Wilcosky T, Walmer DK. Concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) and their associations with human semen quality measurements. Reprod Toxicol. 2012 Jul;33(4):419-27.
[74] Qazi MR, Nelson BD, DePierre JW, Abedi-Valugerdi M. High-dose dietary exposure of mice to perfluorooctanoate or perfluorooctane sulfonate exerts toxic effects on myeloid and B-lymphoid cells in the bone marrow and these effects are partially dependent on reduced food consumption. Food Chem Toxicol. 2012 Sep;50(9):2955-63.
[75] Olsen GW, Lange CC, Ellefson ME, Mair DC, Church TR, Goldberg CL, Herron RM, Medhdizadehkashi Z, Nobiletti JB, Rios JA, Reagen WK, Zobel LR. Temporal trends of perfluoroalkyl concentrations in American Red Cross adult blood donors, 2000-2010. Environ Sci Technol. 2012 Jun 5;46(11):6330-8.
[76] Olsen GW, Ehresman DJ, Buehrer BD, Gibson BA, Butenhoff JL, Zobel LR. Longitudinal assessment of lipid and hepatic clinical parameters in workers involved with the demolition of perfluoroalkyl manufacturing facilities. J Occup Environ Med. 2012 Aug;54(8):974-83.
[77] Loccisano AE, Campbell JL, Jr., Butenhoff JL, Andersen ME, Clewell HJ, 3rd. Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. Reprod Toxicol. 2012 Jul;33(4):452-67.
[78] Loccisano AE, Campbell JL, Jr., Butenhoff JL, Andersen ME, Clewell HJ, 3rd. Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model. Reprod Toxicol. 2012 Jul;33(4):468-90.
[79] Elcombe CR, Elcombe BM, Foster JR, Chang SC, Ehresman DJ, Noker PE, Butenhoff JL. Evaluation of hepatic and thyroid responses in male Sprague Dawley rats for up to eighty-four days following seven days of dietary exposure to potassium perfluorooctanesulfonate. Toxicology. 2012 Mar 11;293(1-3):30-40.
[80] Elcombe CR, Elcombe BM, Foster JR, Chang SC, Ehresman DJ, Butenhoff JL. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARalpha and CAR/PXR. Toxicology. 2012 Mar 11;293(1-3):16-29.
[81] Chang SC, Noker PE, Gorman GS, Gibson SJ, Hart JA, Ehresman DJ, Butenhoff JL. Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys. Reprod Toxicol. 2012 Jul;33(4):428-40.
[82] Butenhoff JL, Pieterman E, Ehresman DJ, Gorman GS, Olsen GW, Chang SC, Princen HM. Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions. Toxicol Lett. 2012 May 5;210(3):360-5.
[83] Butenhoff JL, Kennedy GL, Jr., Chang SC, Olsen GW. Chronic dietary toxicity and carcinogenicity study with ammonium perfluorooctanoate in Sprague-Dawley rats. Toxicology. 2012 Aug 16;298(1-3):1-13.
[84] Butenhoff JL, Chang SC, Olsen GW, Thomford PJ. Chronic dietary toxicity and carcinogenicity study with potassium perfluorooctanesulfonate in Sprague Dawley rats. Toxicology. 2012 Mar 11;293(1-3):1-15.
[85] Butenhoff JL, Bjork JA, Chang SC, Ehresman DJ, Parker GA, Das K, Lau C, Lieder PH, van Otterdijk FM, Wallace KB. Toxicological evaluation of ammonium perfluorobutyrate in rats: twenty-eight-day and ninety-day oral gavage studies. Reprod Toxicol. 2012 Jul;33(4):513-30.
[86] Sundstrom M, Ehresman DJ, Bignert A, Butenhoff JL, Olsen GW, Chang SC, Bergman A. A temporal trend study (1972-2008) of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in pooled human milk samples from Stockholm, Sweden. Environ Int. 2011 Jan;37(1):178-83.

[87] Olsen GW, Ellefson ME, Mair DC, Church TR, Goldberg CL, Herron RM, Medhdizadehkashi Z, Nobiletti JB, Rios JA, Reagen WK, Zobel LR. Analysis of a homologous series of perfluorocarboxylates from American Red Cross adult blood donors, 2000-2001 and 2006. Environ Sci Technol. 2011 Oct 1;45(19):8022-9.

[88] Eriksen KT, Sorensen M, McLaughlin JK, Overvad K, Raaschou-Nielsen O. Determinants of Plasma PFOA and PFOS Levels Among 652 Danish Men. Environ Sci Technol. 2011;45(19):8137-43.

[89] Bogdanska J, Borg D, Sundstrom M, Bergstrom U, Halldin K, Abedi-Valugerdi M, Bergman A, Nelson B, Depierre J, Nobel S. Tissue distribution of (3)(5)S-labelled perfluorooctane sulfonate in adult mice after oral exposure to a low environmentally relevant dose or a high experimental dose. Toxicology. 2011 Jun 18;284(1-3):54-62.

[90] Bjork JA, Butenhoff JL, Wallace KB. Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology. 2011 Oct 9;288(1-3):8-17.

[91] Bijland S, Rensen PC, Pieterman EJ, Maas AC, van der Hoorn JW, van Erk MJ, Havekes LM, Willems van Dijk K, Chang SC, Ehresman DJ, Butenhoff JL, Princen HM. Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden CETP mice. Toxicological sciences : an official journal of the Society of Toxicology. 2011 Sep;123(1):290-303.

[92] York RG, Kennedy GL, Jr., Olsen GW, Butenhoff JL. Male reproductive system parameters in a two-generation reproduction study of ammonium perfluorooctanoate in rats and human relevance. Toxicology. 2010 Apr 30;271(1-2):64-72.

[93] Weaver YM, Ehresman DJ, Butenhoff JL, Hagenbuch B. Roles of rat renal organic anion transporters in transporting perfluorinated carboxylates with different chain lengths. Toxicological sciences : an official journal of the Society of Toxicology. 2010 Feb;113(2):305-14.

[94] Qazi MR, Nelson BD, DePierre JW, Abedi-Valugerdi M. 28-day dietary exposure of mice to a low total dose (7 mg/kg) of perfluorooctanesulfonate (PFOS) alters neither the cellular compositions of the thymus and speen nor humoral immune responses: Does the route of administration play a pivitol role in PFOS-induced immunotoxicity? Toxicology. 2010;267(1-3):132-9.

[95] Qazi M, Abedi MR, Nelson BD, DePierre JW, Abedi-Valugerdi M. Dietary exposure to perfluorooctanoate or perfluorooctane sulfonate induces hypertrophy in cetrilobular hepatocytes and alters the hepatic immune status in mice. International Immunopharmacology. 2010;10(11):1420-7.

[96] Palkar PS, Anderson CR, Ferry CH, Gonzalez FJ, Peters JM. Effect of prenatal peroxisome proliferator-activated receptor α (PPARα) agonism on postnatal development. Toxicology. 2010;276(1):79-84.

[97] Keller JM, Calafat AM, Kato K, Ellefson ME, Reagen WK, Strynar M, O'Connell S, Butt CM, Mabury SA, Small J, Muir DC, Leigh SD, Schantz MM. Determination of perfluorinated alkyl acid concentrations in human serum and milk standard reference materials. Anal Bioanal Chem. 2010 May;397(2):439-51.

[98] Hardisty JF, Willson GA, Brown WR, McConnell EE, Frame SR, Gaylor DW, Kennedy GL, Butenhoff JL. Pathology Working Group review and evaluation of proliferative lesions of mammary gland tissues in female rats fed ammonium perfluorooctanoate (APFO) in the diet for 2 years. Drug Chem Toxicol. 2010 Apr;33(2):131-7.

[99] Elcombe CR, Elcombe BM, Foster JR, Farrar DG, Jung R, Chang SC, Kennedy GL, Butenhoff JL. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARα and CAR/PXR. Arch Toxicol. 2010;84(10):787-98.

[100] Borg D, Bogdanska J, Sundstrom M, Nobel S, Hakansson H, Bergman A, DePierre JW, Halldin K, Bergstrom U. Tissue distribution of ^{35}S-labelled perfluorooctane sulfonate (PFOS) in C57Bl/6 mice following late gestational exposure. Reproductive Toxicology. 2010;30(4):558-65.
[101] Walters MW, Bjork JA, Wallace KB. Perfluorooctanoic acid stimulated mitochondrial biogenesis and gene transcription in rats. Toxicology. 2009 Oct 1;264(1-2):10-5.
[102] Tardiff RG, Carson ML, Sweeney LM, Kirman CR, Tan YM, Andersen M, Bevan C, Gargas ML. Derivation of a drinking water equivalent level (DWEL) related to the maximum contaminant level goal for perfluorooctanoic acid (PFOA), a persistent water soluble compound. Food Chem Toxicol. 2009 Oct;47(10):2557-89.
[103] Qazi MR, Xia Z, Bogdanska J, Chang SC, Ehresman DJ, Butenhoff JL, Nelson BD, DePierre JW, Abedi-Valugerdi M. The atrophy and changes in the cellular compositions of the thymus and spleen observed in mice subjected to short-term exposure to perfluorooctanesulfonate are high-dose phenomena mediated in part by peroxisome proliferator-activated receptor-alpha (PPARalpha). Toxicology. 2009 Jun 16;260(1-3):68-76.
[104] Qazi MR, Bogdanska J, Butenhoff JL, Nelson BD, DePierre JW, Abedi-Valugerdi M. High-dose, short-term exposure of mice to perfluorooctanesulfonate (PFOS) or perfluorooctanoate (PFOA) affects the number of circulating neutrophils differently, but enhances the inflammatory responses of macrophages to lipopolysaccharide (LPS) in a similar fashion. Toxicology. 2009 Aug 21;262(3):207-14.
[105] Olsen GW, Chang SC, Noker PE, Gorman GS, Ehresman DJ, Lieder PH, Butenhoff JL. A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans. Toxicology. 2009 Feb 4;256(1-2):65-74.
[106] Olsen GW, Butenhoff JL, Zobel LR. Perfluoroalkyl chemicals and human fetal development: an epidemiologic review with clinical and toxicological perspectives. Reprod Toxicol. 2009 Jun;27(3-4):212-30.
[107] Lundin JI, Alexander BH, Olsen GW, Church TR. Ammonium perfluorooctanoate production and occupational mortality. Epidemiology. 2009 Nov;20(6):921-8.
[108] Lieder PH, York RG, Hakes DC, Chang SC, Butenhoff JL. A two-generation oral gavage reproduction study with potassium perfluorobutanesulfonate (K+PFBS) in Sprague Dawley rats. Toxicology. 2009 May 2;259(1-2):33-45.
[109] Lieder PH, Chang SC, York RG, Butenhoff JL. Toxicological evaluation of potassium perfluorobutanesulfonate in a 90-day oral gavage study with Sprague-Dawley rats. Toxicology. 2009 Jan 8;255(1-2):45-52.
[110] Foreman JE, Chang SC, Ehresman DJ, Butenhoff JL, Anderson CR, Palkar PS, Kang BH, Gonzalez FJ, Peters JM. Differential hepatic effects of perfluorobutyrate (PFBA) mediated by mouse and human PPARα. Toxicological Sciences. 2009;110(1):204-11.
[111] Eriksen KT, Sorensen M, McLaughlin JK, Lipworth L, Tjonneland A, Overvad K, Raaschou-Nielsen O. Perfluorooctanoate and perfluorooctanesulfonate plasma levels and risk of cancer in the general Danish population. J Natl Cancer Inst. 2009 Apr 15;101(8):605-9.
[112] Chang SC, Ehresman DJ, Bjork JA, Wallace KB, Parker GA, Stump DG, Butenhoff JL. Gestational and lactational exposure to potassium perfluorooctanesulfonate (K+PFOS) in rats: toxicokinetics, thyroid hormone status, and related gene expression. Reprod Toxicol. 2009 Jun;27(3-4):387-99.
[113] Butenhoff JL, Ehresman DJ, Chang SC, Parker GA, Stump DG. Gestational and Lactational Exposure to Potassium Perfluoroctanesulfonate (K^+PFOS) in Rats: Developmental Neurotoxicity. Reproductive Toxicology. 2009;27(3-4):319-30.
[114] Butenhoff JL, Chang SC, Ehresman DJ, York RG. Evaluation of potential reproductive and developmental toxicity of potassium perfluorohexanesulfonate in Sprague Dawley rats. Reprod Toxicol. 2009 Jun;27(3-4):331-41.

[115] Bjork JA, Wallace KB. Structure-activity relationships and human relevance for perfluoroalkyl acid-induced transcriptional activation of peroxisome proliferation in liver cell cultures. Toxicological sciences : an official journal of the Society of Toxicology. 2009 Sep;111(1):89-99.
[116] Tao L, Kannan K, Wong CM, Arcaro KF, Butenhoff JL. Perfluorinated compounds in human milk from Massachusetts, U.S.A. Environ Sci Technol. 2008 Apr 15;42(8):3096-101.
[117] Tan YM, Clewell HJ, 3rd, Andersen ME. Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis. Toxicol Lett. 2008 Feb 28;177(1):38-47.
[118] Reagen WK, Ellefson ME, Kannan K, Giesy JP. Comparison of extraction and quantification methods of perfluorinated compounds in human plasma, serum, and whole blood. Anal Chim Acta. 2008 Nov 3;628(2):214-21.
[119] Olsen GW, Mair DC, Church TR, Ellefson ME, Reagen WK, Boyd TM, Herron RM, Medhdizadehkashi Z, Nobiletti JB, Rios JA, Butenhoff JL, Zobel LR. Decline in perfluorooctanesulfonate and other polyfluoroalkyl chemicals in American Red Cross adult blood donors, 2000-2006. Environ Sci Technol. 2008 Jul 1;42(13):4989-95.
[120] Longnecker MP, Smith CS, Kissling GE, Hoppin JA, Butenhoff JL, Decker E, Ehresman DJ, Ellefson ME, Flaherty J, Gardner MS, Langlois E, Leblanc A, Lindstrom AB, Reagen WK, Strynar MJ, Studabaker WB. An interlaboratory study of perfluorinated alkyl compound levels in human plasma. Environ Res. 2008 Jun;107(2):152-9.
[121] Fei C, McLaughlin JK, Tarone RE, Olsen J. Fetal growth indicators and perfluorinated chemicals: a study in the Danish National Birth Cohort. Am J Epidemiol. 2008 Jul 1;168(1):66-72.
[122] Fei C, McLaughlin JK, Lipworth L, Olsen J. Prenatal exposure to perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS) and maternally reported developmental milestones in infancy. Environ Health Perspect. 2008 Oct;116(10):1391-5.
[123] Das KP, Grey BE, Zehr RD, Wood CR, Butenhoff JL, Chang SC, Ehresman DJ, Tan YM, Lau C. Effects of perfluorobutyrate exposure during pregnancy in the mouse. Toxicological sciences : an official journal of the Society of Toxicology. 2008 Sep;105(1):173-81.
[124] Chang SC, Thibodeaux JR, Eastvold ML, Ehresman DJ, Bjork JA, Froehlich JW, Lau C, Singh RJ, Wallace KB, Butenhoff JL. Thyroid hormone status and pituitary function in adult rats given oral doses of perfluorooctanesulfonate (PFOS). Toxicology. 2008 Jan 20;243(3):330-9.
[125] Chang SC, Das K, Ehresman DJ, Ellefson ME, Gorman GS, Hart JA, Noker PE, Tan YM, Lieder PH, Lau C, Olsen GW, Butenhoff JL. Comparative pharmacokinetics of perfluorobutyrate in rats, mice, monkeys, and humans and relevance to human exposure via drinking water. Toxicological sciences : an official journal of the Society of Toxicology. 2008 Jul;104(1):40-53.
[126] Bjork JA, Lau C, Chang SC, Butenhoff JL, Wallace KB. Perfluorooctane sulfonate-induced changes in fetal rat liver gene expression. Toxicology. 2008 Sep 29;251(1-3):8-20.
[127] Andersen ME, Butenhoff JL, Chang SC, Farrar DG, Kennedy GL, Jr., Lau C, Olsen GW, Seed J, Wallace KB. Perfluoroalkyl acids and related chemistries--toxicokinetics and modes of action. Toxicological sciences : an official journal of the Society of Toxicology. 2008 Mar;102(1):3-14.
[128] Scialli AR, Iannucci A, Turim J. Combining perfluoroalkane acid exposure levels for risk assessment. Regul Toxicol Pharmacol. 2007 Dec;49(3):195-202.
[129] Olsen GW, Zobel LR. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health. 2007 Nov;81(2):231-46.
[130] Olsen GW, Mair DC, Reagen WK, Ellefson ME, Ehresman DJ, Butenhoff JL, Zobel LR. Preliminary evidence of a decline in perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations in American Red Cross blood donors. Chemosphere. 2007 May;68(1):105-11.
[131] Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, Zobel LR. Half-life of serum elimination of perfluorooctanesulfonate,perfluorohexanesulfonate, and

perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 2007 Sep;115(9):1298-305.
[132] Newsted JL, Coady KK, Beach SA, Butenhoff JL, Gallagher S, Giesy JP. Effects of perfluorooctane sulfonate on mallard and northern bobwhite quail exposed chronically via the diet. Environ Toxicol Pharmacol. 2007 Jan;23(1):1-9.
[133] Grice MM, Alexander BH, Hoffbeck R, Kampa DM. Self-reported medical conditions in perfluorooctanesulfonyl fluoride manufacturing workers. J Occup Environ Med. 2007 Jul;49(7):722-9.
[134] Fei C, McLaughlin JK, Tarone RE, Olsen J. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ Health Perspect. 2007 Nov;115(11):1677-82.
[135] Ehresman DJ, Froehlich JW, Olsen GW, Chang SC, Butenhoff JL. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. Environ Res. 2007 Feb;103(2):176-84.
[136] Chang SC, Thibodeaux JR, Eastvold ML, Ehresman DJ, Bjork JA, Froehlich JW, Lau CS, Singh RJ, Wallace KB, Butenhoff JL. Negative bias from analog methods used in the analysis of free thyroxine in rat serum containing perfluorooctanesulfonate (PFOS). Toxicology. 2007 May 5;234(1-2):21-33.
[137] Alexander BH, Olsen GW. Bladder cancer in perfluorooctanesulfonyl fluoride manufacturing workers. Ann Epidemiol. 2007 Jun;17(6):471-8.
[138] Xu L, Krenitsky DM, Seacat AM, Butenhoff JL, Tephly TR, Anders MW. N-glucuronidation of perfluorooctanesulfonamide by human, rat, dog, and monkey liver microsomes and by expressed rat and human UDP-glucuronosyltransferases. Drug Metab Dispos. 2006 Aug;34(8):1406-10.
[139] Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicological sciences : an official journal of the Society of Toxicology. 2006 Aug;92(2):476-89.
[140] O'Brien TM, Carlson RM, Oliveira PJ, Wallace KB. Esterification prevents induction of the mitochondrial permeability transition by N-acetyl perfluorooctane sulfonamides. Chem Res Toxicol. 2006 Oct;19(10):1305-12.
[141] Hinderliter PM, Han X, Kennedy GL, Butenhoff JL. Age effect on perfluorooctanoate (PFOA) plasma concentration in post-weaning rats following oral gavage with ammonium perfluorooctanoate (APFO). Toxicology. 2006 Aug 15;225(2-3):195-203.
[142] Butenhoff JL, Olsen GW, Pfahles-Hutchens A. The applicability of biomonitoring data for perfluorooctanesulfonate to the environmental public health continuum. Environ Health Perspect. 2006 Nov;114(11):1776-82.
[143] Andersen ME, Clewell HJ, 3rd, Tan YM, Butenhoff JL, Olsen GW. Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives. Toxicology. 2006 Oct 3;227(1-2):156-64.
[144] Olsen GW, Huang HY, Helzlsouer KJ, Hansen KJ, Butenhoff JL, Mandel JH. Historical comparison of perfluorooctanesulfonate, perfluorooctanoate, and other fluorochemicals in human blood. Environ Health Perspect. 2005 May;113(5):539-45.
[145] Luebker DJ, York RG, Hansen KJ, Moore JA, Butenhoff JL. Neonatal mortality from in utero exposure to perfluorooctanesulfonate (PFOS) in Sprague-Dawley rats: dose-response, and biochemical and pharamacokinetic parameters. Toxicology. 2005 Nov 5;215(1-2):149-69.

[146] Luebker DJ, Case MT, York RG, Moore JA, Hansen KJ, Butenhoff JL. Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats. Toxicology. 2005 Nov 5;215(1-2):126-48.
[147] Hinderliter PM, Mylchreest E, Gannon SA, Butenhoff JL, Kennedy GL, Jr. Perfluorooctanoate: Placental and lactational transport pharmacokinetics in rats. Toxicology. 2005 Jul 1;211(1-2):139-48.
[148] Flaherty JM, Connolly PD, Decker ER, Kennedy SM, Ellefson ME, Reagen WK, Szostek B. Quantitative determination of perfluorooctanoic acid in serum and plasma by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 25;819(2):329-38.
[149] Butenhoff JL, Gaylor DW, Moore JA, Olsen GW, Rodricks J, Mandel JH, Zobel LR. Author reply to Kropp critique. Regulatory Toxicology and Pharmacology. 2005;42(1):146-7.
[150] Xu L, Krenitsky DM, Seacat AM, Butenhoff JL, Anders MW. Biotransformation of N-ethyl-N-(2-hydroxyethyl)perfluorooctanesulfonamide by rat liver microsomes, cytosol, and slices and by expressed rat and human cytochromes P450. Chem Res Toxicol. 2004 Jun;17(6):767-75.
[151] Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Barbee BD, Richards JH, Butenhoff JL, Stevenson LA, Lau C. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal (Erratum to Toxicol Sci 2003; 74; 369-381). Toxicological sciences : an official journal of the Society of Toxicology. 2004;82(1):359.
[152] Shipley JM, Hurst CH, Tanaka SS, DeRoos FL, Butenhoff JL, Seacat AM, Waxman DJ. trans-activation of PPARalpha and induction of PPARalpha target genes by perfluorooctane-based chemicals. Toxicological sciences : an official journal of the Society of Toxicology. 2004 Jul;80(1):151-60.
[153] Perkins RG, Butenhoff JL, Kennedy GL, Jr., Palazzolo MJ. 13-week dietary toxicity study of ammonium perfluorooctanoate (APFO) in male rats. Drug Chem Toxicol. 2004 Nov;27(4):361-78.
[154] Olsen GW, Church TR, Larson EB, van Belle G, Lundberg JK, Hansen KJ, Burris JM, Mandel JH, Zobel LR. Serum concentrations of perfluorooctanesulfonate and other fluorochemicals in an elderly population from Seattle, Washington. Chemosphere. 2004 Mar;54(11):1599-611.
[155] Olsen GW, Church TR, Hansen KJ, Burris JM, Butenhoff JL, Mandel JH, Zobel LR. Quantitative evaluation of perfluorooctanesulfonate (PFOS) and other fluorochemicals in the serum of children. J Children's Health. 2004;2:53-76.
[156] Olsen GW, Burlew MM, Marshall JC, Burris JM, Mandel JH. Analysis of episodes of care in a perfluorooctanesulfonyl fluoride production facility. J Occup Environ Med. 2004 Aug;46(8):837-46.
[157] O'Brien TM, Wallace KB. Mitochondrial permeability transition as the critical target of N-acetyl perfluorooctane sulfonamide toxicity in vitro. Toxicological sciences : an official journal of the Society of Toxicology. 2004 Nov;82(1):333-40.
[158] Lau C, Butenhoff JL, Rogers JM. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol. 2004 Jul 15;198(2):231-41.
[159] Kennedy GL, Jr., Butenhoff JL, Olsen GW, O'Connor JC, Seacat AM, Perkins RG, Biegel LB, Murphy SR, Farrar DG. The toxicology of perfluorooctanoate. Crit Rev Toxicol. 2004 Jul-Aug;34(4):351-84.
[160] Butenhoff JL, Kennedy GL, Jr., Hinderliter PM, Lieder PH, Jung R, Hansen KJ, Gorman GS, Noker PE, Thomford PJ. Pharmacokinetics of perfluorooctanoate in cynomolgus monkeys. Toxicological sciences : an official journal of the Society of Toxicology. 2004 Dec;82(2):394-406.
[161] Butenhoff JL, Kennedy GL, Jr., Frame SR, O'Connor JC, York RG. The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. Toxicology. 2004 Mar 1;196(1-2):95-116.

[162] Butenhoff JL, Gaylor DW, Moore JA, Olsen GW, Rodricks J, Mandel JH, Zobel LR. Characterization of risk for general population exposure to perfluorooctanoate. Regul Toxicol Pharmacol. 2004 Jun;39(3):363-80.
[163] Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Barbee BD, Richards JH, Butenhoff JL, Stevenson LA, Lau C. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal evaluations. Toxicological sciences : an official journal of the Society of Toxicology. 2003 Aug;74(2):369-81.
[164] Seacat AM, Thomford PJ, Hansen KJ, Clemen LA, Eldridge SR, Elcombe CR, Butenhoff JL. Erratum to "sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats" [Toxicology 183 (2003) 117-131]. Toxicology. 2003;192:263-4.
[165] Seacat AM, Thomford PJ, Hansen KJ, Clemen LA, Eldridge SR, Elcombe CR, Butenhoff JL. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology. 2003 Feb 1;183(1-3):117-31.
[166] Olsen GW, Logan PW, Hansen KJ, Simpson CA, Burris JM, Burlew MM, Vorarath PP, Venkateswarlu P, Schumpert JC, Mandel JH. An occupational exposure assessment of a perfluorooctanesulfonyl fluoride production site: biomonitoring. AIHA J (Fairfax, Va). 2003 Sep-Oct;64(5):651-9.
[167] Olsen GW, Hansen KJ, Stevenson LA, Burris JM, Mandel JH. Human donor liver and serum concentrations of perfluorooctanesulfonate and other perfluorochemicals. Environ Sci Technol. 2003 Mar 1;37(5):888-91.
[168] Olsen GW, Church TR, Miller JP, Burris JM, Hansen KJ, Lundberg JK, Armitage JB, Herron RM, Medhdizadehkashi Z, Nobiletti JB, O'Neill EM, Mandel JH, Zobel LR. Perfluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors. Environ Health Perspect. 2003 Dec;111(16):1892-901.
[169] Olsen GW, Burris JM, Burlew MM, Mandel JH. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med. 2003 Mar;45(3):260-70.
[170] Lau C, Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Stanton ME, Butenhoff JL, Stevenson LA. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: postnatal evaluation. Toxicological sciences : an official journal of the Society of Toxicology. 2003 Aug;74(2):382-92.
[171] Alexander BH, Olsen GW, Burris JM, Mandel JH, Mandel JS. Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup Environ Med. 2003 Oct;60(10):722-9.
[172] Starkov AA, Wallace KB. Structural determinants of fluorochemical-induced mitochondrial dysfunction. Toxicological sciences : an official journal of the Society of Toxicology. 2002 Apr;66(2):244-52.
[173] Seacat AM, Thomford PJ, Hansen KJ, Olsen GW, Case MT, Butenhoff JL. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicological sciences : an official journal of the Society of Toxicology. 2002 Jul;68(1):249-64.
[174] Luebker DJ, Hansen KJ, Bass NM, Butenhoff JL, Seacat AM. Interactions of fluorochemicals with rat liver fatty acid-binding protein. Toxicology. 2002 Jul 15;176(3):175-85.
[175] Hansen KJ, Johnson HO, Eldridge JS, Butenhoff JL, Dick LA. Quantitative characterization of trace levels of PFOS and PFOA in the Tennessee River. Environ Sci Technol. 2002 Apr 15;36(8):1681-5.
[176] Butenhoff J, Costa G, Elcombe C, Farrar D, Hansen K, Iwai H, Jung R, Kennedy G, Jr., Lieder P, Olsen G, Thomford P. Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicological sciences : an official journal of the Society of Toxicology. 2002 Sep;69(1):244-57.

[177] Berthiaume J, Wallace KB. Perfluorooctanoate, perflourooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. Toxicol Lett. 2002 Mar 24;129(1-2):23-32.
[178] Case MT, York RG, Christian MS. Rat and rabbit oral developmental toxicology studies with two perfluorinated compounds. Int J Toxicol. 2001 Mar-Apr;20(2):101-9.
[179] Olsen GW, Burris JM, Burlew MM, Mandel JH. Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. Drug Chem Toxicol. 2000 Nov;23(4):603-20.
[180] Olsen GW, Burris JM, Mandel JH, Zobel LR. Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J Occup Environ Med. 1999 Sep;41(9):799-806.
[181] Olsen GW, Gilliland FD, Burlew MM, Burris JM, Mandel JS, Mandel JH. An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. J Occup Environ Med. 1998 Jul;40(7):614-22.
[182] Gilliland FD, Mandel JS. Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men. Am J Ind Med. 1996 May;29(5):560-8.
[183] Gilliland FD, Mandel JS. Mortality among employees of a perfluorooctanoic acid production plant. J Occup Med. 1993 Sep;35(9):950-4.
[184] Johnson JD, Gibson SJ, Ober RE. Cholestyramine-enhanced fecal elimination of carbon-14 in rats after administration of ammonium [14C]perfluorooctanoate or potassium [14C]perfluorooctanesulfonate. Fundam Appl Toxicol. 1984 Dec;4(6):972-6.
[185] Ubel FA, Sorenson SD, Roach DE. Health status of plant workers exposed to fluorochemicals--a preliminary report. Am Ind Hyg Assoc J. 1980 Aug;41(8):584-9.
[186] Griffith FD, Long JE. Animal toxicity studies with ammonium perfluorooctanoate. Am Ind Hyg Assoc J. 1980 Aug;41(8):576-83.